Previous 10 | Next 10 |
2024-06-01 11:05:00 ET More on GSK, Pfizer GSK wins first Zantac cancer jury trial (updated) GSK faces another Zantac whistleblower lawsuit GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Tu...
2024-06-01 08:54:00 ET When it comes to dividend investing, some investors like to invest for income, and if you are searching for income, this is the video for you. Today, we will be looking at three dividend stocks that pay huge dividends, all with yields above 5%, one of which is Pfize...
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone, resulting in median overall survival of 13.8 months versus 8.5 months Third Phase 3 trial in third type of lymphoma to show improveme...
− Four-year Analysis Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing Superior Efficacy and Tolerable Safety Profile in Patients with Newly Diagnosed Stage IIb/III/IV Classical Hodgkin Lymphoma vs eBEACOPP, a Current Standard of Care i...
2024-05-31 12:19:46 ET More on Novartis Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis reports positive Phase 3 data for remibrutinib for chronic hives Novartis end...
2024-05-31 11:11:00 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued Third human bird flu case found in U.S. ...
2024-05-31 09:48:36 ET More on Pfizer Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Pfizer: Down To A Historically Low Valuation - Is It A Buy? Pfizer gene therapy for haemophilia B therapy endors...
2024-05-31 08:13:08 ET More on Pfizer Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Pfizer: Down To A Historically Low Valuation - Is It A Buy? Third human bird flu case found in U.S. New ...
An unprecedented 60% of patients remain alive without disease progression after five years Updated results show continued 81% reduction in risk of progression or death and 94% reduction in progression of brain metastases compared to XALKORI ® Pfizer Inc. (NYSE: PFE) t...
2024-05-31 03:30:00 ET Fool.com contributor Parkev Tatevosian reviews Pfizer (NYSE: PFE) stock for passive income investors. *Stock prices used were the afternoon prices of May 28, 2024. The video was published on May 30, 2024. Continue reading For further de...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...